Looking to read the full article? Subscribe to BioWorld Asia.

Bridge Biotherapeutics receives MFDS approval for EGFR drug in lung cancer

May 12, 2020

HONG KONG – South Korea’s Bridge Biotherapeutics Inc. wrapped up the week by announcing its awaited IND clearance for its epidermal growth factor receptor tyrosine kinase inhibitor, BBT-176, for non-small-cell lung cancer.

Asia-Pacific BioWorld Asia Cancer Regulatory

Already a subscriber? Sign in

Quest launches consumer-initiated, antibody test for COVID-19

BioWorld MedTech

The capacity of U.S. medical providers and testing capacity for the unfolding COVID-19 pandemic continues to be sorely tested. But there is now a new route for...

Today's news in brief

BioWorld

BioWorld briefs for May 22.

Mexican flag, coronavirus vaccine vial, syringe

Mexican team led by vets racing to develop COVID-19 vaccine

BioWorld

CAJICA, Colombia – A research team at the Autonomous University of Queretaro (UAQ), Mexico, is working to develop a COVID-19 vaccine, joining about 100 other...

Shortage of needles, syringes looms in race to develop COVID-19 vaccine

BioWorld

In the rush to develop a COVID-19 vaccine, integral parts of the equation are being overlooked in the U.S., according to a whistleblower complaint filed this week...

Roche snags FDA nod for COVID-19 antibody test

BioWorld MedTech

Roche Holding AG, of Basel, Switzerland, has garnered U.S. FDA authorization for emergency use of a test to determine whether people have been infected with the...